image
Healthcare - Biotechnology - NASDAQ - FR
$ 3.1281
-5.72 %
$ 302 M
Market Cap
-0.9
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 22, 2025.

The intrinsic value of one IVA stock under the worst case scenario is HIDDEN Compared to the current market price of 3.13 USD, Inventiva S.A. is HIDDEN

This DCF valuation model was last updated on May, 22, 2025.

The intrinsic value of one IVA stock under the base case scenario is HIDDEN Compared to the current market price of 3.13 USD, Inventiva S.A. is HIDDEN

This DCF valuation model was last updated on May, 22, 2025.

The intrinsic value of one IVA stock under the best case scenario is HIDDEN Compared to the current market price of 3.13 USD, Inventiva S.A. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IVA

image
$4.0$4.0$3.8$3.8$3.6$3.6$3.4$3.4$3.2$3.2$3.0$3.0$2.8$2.8$2.6$2.6$2.4$2.4$2.2$2.2$2.0$2.0Dec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 May
FINANCIALS
9.2 M REVENUE
-47.37%
-97.6 M OPERATING INCOME
5.02%
-184 M NET INCOME
-66.82%
-85.9 M OPERATING CASH FLOW
-5.29%
8.74 M INVESTING CASH FLOW
213.12%
146 M FINANCING CASH FLOW
400.64%
2.73 M REVENUE
-83.47%
-52.2 M OPERATING INCOME
-9.52%
-49 M NET INCOME
11.11%
-48.3 M OPERATING CASH FLOW
-32.88%
8.91 M INVESTING CASH FLOW
30831.03%
22.6 M FINANCING CASH FLOW
-27.75%
Balance Sheet Inventiva S.A.
image
Current Assets 112 M
Cash & Short-Term Investments 96.6 M
Receivables 12.2 M
Other Current Assets 2.79 M
Non-Current Assets 7.46 M
Long-Term Investments 1.14 M
PP&E 5 M
Other Non-Current Assets 1.31 M
81.17 %10.22 %4.21 %Total Assets$119.0m
Current Liabilities 121 M
Accounts Payable 32.9 M
Short-Term Debt 5.87 M
Other Current Liabilities 82 M
Non-Current Liabilities 105 M
Long-Term Debt 48.5 M
Other Non-Current Liabilities 56.4 M
14.57 %36.35 %21.48 %25.01 %Total Liabilities$225.6m
EFFICIENCY
Earnings Waterfall Inventiva S.A.
image
Revenue 9.2 M
Cost Of Revenue 0
Gross Profit 9.2 M
Operating Expenses 107 M
Operating Income -97.6 M
Other Expenses 86.7 M
Net Income -184 M
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)(200m)(200m)9m09m(107m)(98m)(87m)(184m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
62.47% GROSS MARGIN
62.47%
-662.58% OPERATING MARGIN
-662.58%
-1251.10% NET MARGIN
-1251.10%
172.73% ROE
172.73%
-154.84% ROA
-154.84%
-2381.19% ROIC
-2381.19%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Inventiva S.A.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)(90m)(90m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -184 M
Depreciation & Amortization 5.2 M
Capital Expenditures -333 K
Stock-Based Compensation 3.58 M
Change in Working Capital 1.68 M
Others 91.1 M
Free Cash Flow -86.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Inventiva S.A.
image
IVA has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 18
6. Ownership
Insider Ownership Inventiva S.A.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the “Structured Financing”), for gross proceeds of €115.6 million (net proceeds of €108.5 million) (the “T2 Transaction”). globenewswire.com - 4 weeks ago
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents Daix (France), New York City (New York, United States), April 30,  2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the availability of the preparatory documents for the Combined General Meeting of May 22, 2025. globenewswire.com - 1 month ago
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor ► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis globenewswire.com - 1 month ago
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F Daix (France),  New York City (New York, United States), April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that it had filed its 2024 Universal Registration Document for the year ended December 31, 2024, including the management report and the annual financial report, with the French “Autorité des Marchés Financiers” (“AMF”) and its 2024 Annual Report on Form 20-F for the year ended December 31, 2024 with the U.S. Securities and Exchange Commission (“SEC”). globenewswire.com - 1 month ago
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis Daix (France), New York City (New York, United States), April 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced the completion of patient enrollment in its NATiV3 Phase 3 clinical trial with the randomization of the last patient in the main cohort. Inventiva has enrolled 1009 patients in the main cohort and 410 patients in the exploratory cohort exceeding the original target of 969 and 350, respectively. globenewswire.com - 2 months ago
Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript Inventiva S.A. (NASDAQ:IVA ) Q4 2024 Earnings Call March 27, 2025 8:00 AM ET Company Participants Frédéric Cren - CEO Jean Volatier - CFO Pierre Broqua - CSO Conference Call Participants Unidentified Analyst - TD Cowen Unidentified Analyst - Jefferies & Co. Annabel Samimy - Stifel Ed Arce - HC Wainwright Jacob Mekhael - KBC Securities Rami Katkhuda - LifeSci Capital Unidentified Analyst - UBS Operator Good day and thank you for standing by. seekingalpha.com - 2 months ago
Inventiva reports its 2024 full year results and provides a business update Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), and other diseases with significant unmet medical needs, today reported its financial results for the full year ended December 31, 2024 and also provided a business update. globenewswire.com - 2 months ago
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. globenewswire.com - 2 months ago
Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment Daix (France), New York City (New York, United States), February 26, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced the publication in Biomedicine & Pharmacotherapy, a peer-reviewed, scientific journal, of the results from a preclinical study demonstrating that lanifibranor may reduce Portal Hypertension (“PH”). globenewswire.com - 3 months ago
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial Daix (France), New York City (New York, United States), Tokyo (Japan), February 20,  2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, and Hepalys Pharma, Inc. (“Hepalys”), a company incorporated in Japan and founded by Catalys Pacific, announced today the initiation of the clinical development program of lanifibranor in Japan with the first Japanese participant dosed in a Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics (“PK”) and pharmacodynamics (“PD”) of lanifibranor. globenewswire.com - 3 months ago
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update Daix (France), New York City (New York, United States), February 10, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), and other diseases with significant unmet medical needs, today reported certain preliminary unaudited financial results for the full year ended December 31, 2024, including cash, cash equivalents, and revenues, and also provided a business update. globenewswire.com - 3 months ago
Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of Hepatology Daix (France), New York City (New York, United States), January 29, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced the publication in Journal of Hepatology, a peer-reviewed scientific journal, of the results from the investigator-initiated clinical study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with type 2 diabetes (“T2D”) and Metabolic dysfunction-Associated Liver Disease (“MASLD”)1. The clinical trial demonstrated significant improvement of hepatic, muscle and adipose tissue insulin resistance in patients with MASLD and T2D treated with lanifibranor. globenewswire.com - 4 months ago
8. Profile Summary

Inventiva S.A. IVA

image
COUNTRY FR
INDUSTRY Biotechnology
MARKET CAP $ 302 M
Dividend Yield 0.00%
Description Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Contact 50 rue de Dijon, Daix, 21121 https://www.inventivapharma.com
IPO Date July 10, 2020
Employees 114
Officers Ms. Pascaline Clerc Ph.D. Executive Vice President of Strategy & Corporate Affairs Dr. Michael Cooreman M.D., Ph.D. Chief Medical Officer Mr. Eric Duranson L.L.M. General Counsel Ms. Nathalie Harroy Head of Human Resources Ms. Alice Roudot-Ketelers Pharm.D. Chief Operating Officer Mr. Frederic Cren Co-Founder, Chief Executive Officer & Director Mr. Jean Volatier Deputy GM & Chief Financial Officer Dr. Kristina Meyer Ph.D. Executive Vice President and Business Development & Alliance Management Dr. Pierre Broqua Ph.D. Co-Founder, Chief Scientific Officer & Deputy Chief Executive Officer